Nykredit A S Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Nykredit A/S purchased 443,442 Teva shares during the second quarter, a new position valued at approximately $15 million. Institutional investors collectively own 54.05% of Teva’s stock.
• Analyst sentiment remains positive: nine analysts rate TEVA as a Buy and one as a Hold, producing a consensus “Moderate Buy” rating and a $42.89 price target. UBS recently raised its target to $48, while Piper Sandler and Barclays also increased their targets.
• Teva shares opened at $36.36, near their 52-week high of $38.37, while the company reported quarterly revenue of $4.14 billion and EPS of $0.02. Insider activity was negative, with an executive selling 106,563 shares and no reported insider purchases over the past six months.

Nykredit A S purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 443,442 shares of the company's stock, valued at approximately $15,024,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $25,000. Cornerstone Planning Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after buying an additional 755 shares during the last quarter. Allworth Financial LP grew its holdings in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after buying an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock worth $32,000 after buying an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC raised its position in Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock valued at $42,000 after buying an additional 292 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TEVA. Wall Street Zen cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, August 21st. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an "overweight" rating in a research report on Tuesday, July 28th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Finally, UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a research note on Friday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.89.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

Teva Pharmaceutical Industries Stock Down 0.7%

Shares of NYSE:TEVA opened at $36.36 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $18.21 and a 1 year high of $38.37. The company has a market capitalization of $42.37 billion, a PE ratio of 60.60, a price-to-earnings-growth ratio of 4.57 and a beta of 0.87. The business has a fifty day moving average price of $34.64 and a two-hundred day moving average price of $33.28. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Eliyahu Kalif sold 106,563 shares of the business's stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president directly owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.54% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source